Two independent diagnostic advances highlight liquid biopsy momentum. VolitionRx published a preprint describing Capture‑Seq, a ChIP‑Seq adaptation targeting cell‑free CTCF‑DNA complexes; the method enriched ultrashort CTCF‑bound fragments and revealed cancer‑specific binding sites in plasma samples, offering a new class of epigenetic liquid‑biopsy biomarkers. Personalis published Phase I data showing its NeXT Personal MRD whole‑genome ctDNA assay predicted immunotherapy response across 24 tumor types, with early ctDNA declines correlating with improved PFS and OS. Both approaches emphasize enhanced sensitivity and earlier, tumor‑agnostic monitoring capabilities. VolitionRx’s Capture‑Seq focuses on novel biomarker classes (cfCTCF‑DNA occupancy), while Personalis provides clinical validation linking ctDNA dynamics to outcomes. Further validation, standardization, and prospective utility studies are required before regulatory and clinical adoption.